Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Abstract af OMF-finansieret studie om røde blodlegemers deformabilitet

Vi er glade for at kunne dele, at den OMF-finansierede forskning i røde blodlegemers deformabilitet af Mohsen Nemat-Gorgani, PhD på Stanford University, og Anand Ramasubramanian, PhD på San Jose State University, i samarbejde med Ron Davis, PhD, og deres medarbejdere, netop er blevet offentliggjort i det videnskabelige tidsskrift Blood Journal og er blevet antaget til publikation i Clinical Hemorheology and Microcirculation. De vigtige forskningsresultater kan potentielt lede til en biomarkør og diagnostisk test.

Studiet er fuldt og helt sponsoreret af Open Medicine Foundation (OMF) via støtte fra vores generøse donorer. Læs Dr. Ron Davis’ resumé og det videnskabelige abstract nedenfor. Sammen gør vi vigtige opdagelser dagligt og kommer tættere på at finde svar.

Resumé skrevet af Ronald W. Davis, PhD

Artiklen dokumenterer, at røde blodlegemer er mindre deformerbare hos ME / CFS-patienter sammenlignet med raske kontrolpersoner. Det kunne potentielt være en biomarkør, og vi er i gang med at designe et nyt apparat, som kan skelne klart mellem patienter og raske kontrolpersoner. Apparaterne vil være håndholdte og nemme at bruge for læger i deres konsultation eller i kliniske laboratorier. Tidligere forskning har primært beskæftiget sig med de røde blodlegemers form, hvilket er vanskeligt at opgøre. Vores apparat vil give et klart kvantitativt tal. Det måler de røde blodlegemers evne til at ændre form, idet de bliver presset ind i kapillærerne – noget blodlegemer skal være i stand til at gøre for at sikre sund blodgennemstrømning. Vi har målt hundredevis af celler fra hver patient, så selvom antallet af patienter er lavt, har vi været i stand til at finde en statistisk signifikant forskel mellem cellernes deformerbarhed hos patienter og raske kontrolpersoner. Vi arbejder målrettet på at udvikle de nye apparater så hurtigt som muligt.

Erythrocyte Deformability As a Potential Biomarker for Chronic Fatigue Syndrome (Blood Journal, Nov. 2018):

Authors: Amit K. Saha, Brendan R. Schmidt, Julie Wilhelmy, Vy Nguyen, Justin Do, Vineeth C. Suja, Mohsen Nemat-Gorgani, Anand K. Ramasubramanian and Ronald W. Davis

“Vores data demonstrerer, at de røde blodlegemers signifikant reducerede deformerbarhed hos ME / CFS-patienter muligvis er et resultat af oxidativ stress og antyder, at ændret mikrovaskulær perfusion kan være en mulig årsag til ME / CFS-symptomer. Vores data tyder også på, at de røde blodlegemers deformerbarhed potentielt kan bruges som biomarkør for ME / CFS, selvom yderligere studier er nødvendige for en ikke-specifik klassifikation af sygdommen.”

Læs det originale indlæg i Blood Journal 

OMF takker Bernadette Alster for oversættelsen.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo